Company: DRTSW
Filing Date: 2025-06-23
Form Type: F-3
Source: 0001213900-25-056744
Chunk: 5

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-06-23
Form: F-3
Chunk 5
---
, and if we are unable to raise capital when needed, we could be forced to delay, reduce or terminate the development of the Alpha 
 DaRT technology or other product discovery and development programs or commercialization efforts;                                         |

| ● | Our limited operating history                                                                                     
 may make it difficult for you to evaluate the success of our business to date and to assess its future viability; |

| ● | Our approach to the development                                                                                                      
 of our proprietary Alpha DaRT technology represents a novel approach to radiation therapy, which creates significant and potentially 
 unpredictable challenges for us;                                                                                                     |

| ● | The commercial success of our                                                                                                             
 Alpha DaRT technology, if authorized or certified for commercial sale, will depend in part upon public perception of radiation therapies, 
 and to a lesser extent, radiopharmaceuticals, and the degree of their market acceptance by physicians, patients, healthcare payors and    
 others in the medical community;                                                                                                          |

| ● | The market opportunities for                                                                                                           
 our Alpha DaRT technology may be smaller than we anticipated or may be limited to those patients who are ineligible for or have failed 
 prior treatments. If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be 
 delayed or otherwise adversely affected;                                                                                               |

| ● | We do not currently engage                                                                                                                    
 in commercial marketing activities or sales efforts and have no experience in marketing our products. If we are unable to establish marketing 
 and sales capabilities or enter into agreements with third parties to market and sell our Alpha DaRT technology, if approved or certified     
 for commercial sale, we may not be able to generate product revenue;                                                                          |

| ● | We currently conduct, and in                                                                                                         
 the future intend to continue conduct, preclinical studies, clinical trials for our Alpha DaRT technology outside the United States, 
 and the FDA (as defined below) and similar foreign regulatory authorities may not accept data from such trials;                      |

| ● | Our Alpha DaRT technology and                                                                                                           
 operations are subject to extensive government regulation and oversight both in the United States and abroad, and our failure to comply 
 with applicable requirements could harm our business;                                                                                   |

<div align='center'>ii</div>

| ● | We may not receive, or may                                                                                                                
 be delayed in receiving, the necessary marketing authorizations or certifications for our Alpha DaRT technology or any future products    
 or product candidates, and failure to timely obtain necessary marketing authorizations or certifications for our product candidates would 
 have a material adverse effect on our